2025
SJR Q2
JCR Q2 · 3,5
158 eşleşen makale
SCIE
Dergi ayrıntısı
Peptides
- Yayıncı
- Elsevier Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0196978118735169
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,009
- Quartile Q2
- H-Index 148
- Atıf/yayın 3,23
- Doküman (3y) 347
- Atıf (3y) 1.139
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,5
- 5Y JIF 3,4
- JCI 0,78
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Biochemistry Q2
- Cellular and Molecular Neuroscience Q2
- Endocrinology Q2
- Physiology Q2
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Neuroscience
WoS kategorileri
- Biochemistry & Molecular Biology | Endocrinology & Metabolism | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 1,009 | 3,5 | 3,4 | 0,78 | Q2 | 148 |
| 2024 | Q2 | Q2 | 0,958 | 2,9 | 3,2 | 0,77 | Q2 | 144 |
| 2023 | Q2 | Q2 | 0,826 | 2,8 | 2,9 | 0,65 | Q2 | 144 |
| 2022 | Q2 | Q3 | 0,75 | 3 | 3,1 | 0,69 | Q2 | 144 |
| 2021 | Q2 | Q2 | 0,873 | 3,9 | 3,6 | 0,76 | Q2 | 144 |
| 2020 | Q2 | Q2 | 0,818 | 3,8 | 3,4 | 0,81 | Q2 | 144 |
| 2019 | Q2 | Q2 | 0,878 | 2,8 | 2,9 | 0,83 | Q2 | 144 |
| 2018 | — | Q2 | — | 2,7 | 2,7 | 0,79 | Q2 | — |
| 2017 | Q2 | Q2 | 1,001 | 2,9 | 2,8 | 0,83 | Q2 | 144 |
| 2016 | Q2 | Q2 | 0,939 | 2,8 | 2,6 | — | — | 144 |
| 2015 | Q2 | Q2 | 1,103 | 2,5 | 2,5 | — | — | 144 |
| 2014 | Q2 | Q2 | 0,964 | 2,6 | 2,4 | — | — | 144 |
| 2013 | Q2 | Q2 | 0,979 | 2,6 | 2,6 | — | — | 144 |
| 2012 | Q2 | Q2 | 0,809 | 2,5 | 2,5 | — | — | 144 |
| 2011 | Q2 | Q2 | 0,873 | 2,4 | 2,5 | — | — | 144 |
| 2010 | Q2 | Q2 | 0,917 | 2,7 | 2,5 | — | — | 144 |
| 2009 | — | Q2 | — | 2,7 | 2,6 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | 2,5 | — | — | — |
| 2007 | — | Q2 | — | 2,4 | 2,4 | — | — | — |
| 2006 | — | Q2 | — | 2,7 | — | — | — | — |
| 2005 | — | Q2 | — | 2,2 | — | — | — | — |
| 2004 | — | Q2 | — | 2,5 | — | — | — | — |
| 2003 | — | Q2 | — | 2,4 | — | — | — | — |
| 2002 | — | Q1 | — | 2,6 | — | — | — | — |
| 2001 | — | Q2 | — | 2,1 | — | — | — | — |
| 2000 | — | Q3 | — | 1,9 | — | — | — | — |
| 1999 | — | Q2 | — | 2,2 | — | — | — | — |
| 1998 | — | Q2 | — | 2 | — | — | — | — |
| 1997 | — | Q2 | — | 1,7 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q2 | 163/328 |
| 2025 | ENDOCRINOLOGY & METABOLISM | SCIE | Q2 | Q2 | 87/198 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 134/356 |
| 2024 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 182/320 |
| 2024 | ENDOCRINOLOGY & METABOLISM | SCIE | Q2 | Q2 | 96/193 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 150/352 |
| 2023 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 184/313 |
| 2023 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q3 | 97/186 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 158/354 |
| 2022 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 181/285 |
| 2022 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q3 | 99/145 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 157/278 |
| 2021 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 169/297 |
| 2021 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 81/146 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 123/279 |
| 2020 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 157/295 |
| 2020 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 81/146 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 124/276 |
| 2019 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 170/297 |
| 2019 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 89/143 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 123/271 |
| 2018 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 161/299 |
| 2018 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 88/145 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 130/267 |
| 2017 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 152/293 |
| 2017 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 83/142 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 104/261 |
| 2016 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 146/290 |
| 2016 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 73/138 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 104/257 |
| 2015 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 158/289 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 109/255 |
| 2014 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 150/290 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 108/255 |
| 2013 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 165/291 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 103/256 |
| 2012 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 170/290 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 110/261 |
| 2011 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 177/290 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 114/261 |
| 2010 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 151/286 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 99/252 |
| 2009 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 134/283 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 93/237 |
| 2008 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 143/275 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/219 |
| 2007 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 141/263 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 84/205 |
| 2006 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 121/262 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/199 |
| 2005 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 138/261 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 76/193 |
| 2004 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 122/261 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 56/187 |
| 2003 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 119/261 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 53/185 |
| 2002 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 103/266 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/188 |
| 2001 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 135/308 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 51/186 |
| 2000 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 156/310 |
| 1999 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 121/295 |
| 1998 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 120/295 |
| 1997 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 125/253 |